Literature DB >> 29480364

Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.

Jie Cui1,2, Min-Cong Wang3, Ya-Min Zhang1,2, Ming-Zhi Ren1,2, Shi-Xiong Wang1,2, Ke-Jun Nan4, Li-Ping Song5.   

Abstract

OBJECTIVE: To investigate the potential radiosensitization of S-1 and gefitinib in human non-small cell lung cancer (NSCLC) in vitro and in vivo.
METHODS: The impact of radiation, 5-fluorouracil (5-Fu), and gefitinib on the proliferation and apoptosis of human NSCLC A549, H1299, H1975, and HCC827 cells was examined by MTT and flow cytometry. The effect of radiation, 5-Fu, and gefitinib on the clonogenicity of H1975 and HCC827 cells was determined by colony formation assay. The effect of radiation, 5-fluorouracil (5-Fu), and gefitinib on the EGFR, AKT, and ERK1/2 activation in H1975 cells was determined by Western blot. The therapeutic efficacy of radiation, S-1, and gefitinib in the growth of implanted H1975 tumors and the AKT activation in the tumors were examined in vivo and immunohistochemistry, respectively.
RESULTS: Combination of radiation, 5-Fu, and gefitinib significantly inhibited the proliferation of H1975 cells and triggered their apoptosis, but not other NSCLC cells tested. The combination therapy significantly mitigated the clonogenicity and attenuated the activation of EGFR and AKT signaling in H1975 cells. Furthermore, combination of S-1, gefitinib, and radiation significantly inhibited the growth of implanted H1975 tumors in mice and remarkably reduced the AKT phosphorylation in the tumors.
CONCLUSIONS: Our data indicated that combination of S-1 and gefitinib significantly increased radiosensitivity of H1975 cells. The triple combination therapies may benefit patients with the EGFR T790M mutant NSCLC.

Entities:  

Keywords:  Gefitinib; NSCLC; Radiosensitization; S-1

Mesh:

Substances:

Year:  2018        PMID: 29480364     DOI: 10.1007/s00280-018-3539-2

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  2 in total

1.  Gefitinib Inhibits Rifampicin-Induced CYP3A4 Gene Expression in Human Hepatocytes.

Authors:  Kodye L Abbott; Julia M Salamat; Patrick C Flannery; Chloe S Chaudhury; Aneesh Chandran; Saraswathi Vishveshwara; Sridhar Mani; Jianfeng Huang; Amit K Tiwari; Satyanarayana R Pondugula
Journal:  ACS Omega       Date:  2022-09-13

2.  Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone.

Authors:  Yujia Wang; Guoyu Wu; Ru Li; Yingzhe Luo; Xingmei Huang; Lifang He; Huihui Zhong; Shaoquan Xiong
Journal:  Front Public Health       Date:  2021-06-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.